Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 20/20 | 1.00 |
| ▸ | HTR1B | P28222 | 17/20 | 1.00 |
| ▸ | HTR1A | P08908 | 3/20 | 1.00 |
| ▸ | HTR1F | P30939 | 3/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.79 |
| ▸ | DRD2 | P14416 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8604274 | 0.99 | HTR1D (0.98) | HTR1DHTR1BHTR1AHTR1FCHRM2 | |
| Fumaric Acid SCHEMBL7485328 | 0.94 | HTR1D (0.89) | HTR1DHTR1BHTR1AHTR1FCHRM2 | |
| Fumaric Acid SCHEMBL7485333 | 0.94 | HTR1D (0.89) | HTR1DHTR1BHTR1AHTR1FCHRM2 | |
| SCHEMBL7017007 | 0.92 | HTR1D (0.85) | HTR1DHTR1BHTR1AHTR1FCHRM2 | |
| SCHEMBL7480604 | 0.91 | HTR1D (0.83) | HTR1DHTR1BHTR1AHTR1FCHRM2 | |
| SCHEMBL7482014 | 0.91 | HTR1D (0.83) | HTR1DHTR1BHTR1AHTR1FCHRM2 | |
| SCHEMBL7489955 | 0.90 | HTR1D (0.82) | HTR1DHTR1BHTR1AHTR1FCHRM2 | |
| SCHEMBL7486063 | 0.90 | HTR1D (0.81) | HTR1DHTR1BHTR1AHTR1FCHRM2 | |
| SCHEMBL7483636 | 0.90 | HTR1D (0.81) | HTR1DHTR1BHTR1AHTR1FCHRM2 | |
| SCHEMBL7484191 | 0.90 | HTR1D (0.81) | HTR1DHTR1BHTR1AHTR1FCHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125645-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | VALORISATION HSJ LP (CA) | 2026-05-07 | — | — | US | claimed |
| WO-2024073845-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | VALORISATION HSJ, LIMITED PARTNERSHIP (CA) | 2024-04-11 | — | — | WO | claimed |
| EP-1239878-B1 | FORMULATIONS OF ADENOSINE A1 AGONISTS AND 5HT1 AGONISTS | GLAXO GROUP LTD (GB) | 2004-02-25 | — | — | EP | claimed |
| EP-0733628-B9 | 5-Substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)- and 3-(piperidin-4-yl)-1H-indoles: 5-HT1F agonists | LILLY CO ELI (US) | 2002-06-12 | — | — | EP | claimed |
| EP-0733628-B1 | 5-Substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)- and 3-(piperidin-4-yl)-1H-indoles: 5-HT1F agonists | LILLY CO ELI (US) | 2000-12-27 | — | — | EP | claimed |
| US-5962473-A | Methods of treating or ameliorating the symptoms of common cold or allergic rhinitis with serotonin 5-HT1F | ELI LILLY AND COMPANY (US) | 1999-10-05 | — | — | US | claimed |
| EP-0832650-A2 | Use of serotonin 5-HT1F agonists for the prevention of migraine | ELI LILLY AND COMPANY (US) | 1998-04-01 | — | — | EP | claimed |
| WO-1998011895-A1 | A METHOD FOR THE PREVENTION OF MIGRAINE | ELI LILLY AND COMPANY (US) | 1998-03-26 | — | — | WO | claimed |
| EP-0824917-A2 | Use of a serotonin 5-HTlf agonist in the manufacture of a medicament for treating or ameliorating the symptoms of common cold or allergic rhinitis | ELI LILLY AND COMPANY (US) | 1998-02-25 | — | — | EP | claimed |
| WO-1998006402-A1 | TREATMENT OF THE COMMON COLD OR ALLERGIC RHINITIS | ELI LILLY AND COMPANY (US) | 1998-02-19 | — | — | WO | claimed |
| US-5708008-A | TREATMENT OF MIGRAINE | ELI LILLY AND COMPANY (US) | 1998-01-13 | — | — | US | claimed |
| US-20260125645-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | VALORISATION HSJ LP (CA) | 2026-05-07 | — | — | US | disclosed |
| US-20250262268-A1 | Methods and Compositions for Inhibiting Viral Infection | NEW YORK UNIVERSITY | 2025-08-21 | — | — | US | disclosed |
| WO-2024073845-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | VALORISATION HSJ, LIMITED PARTNERSHIP (CA) | 2024-04-11 | — | — | WO | disclosed |
| US-11939301-B2 | 5HT1F receptor agonists and mitochondrial biogenesis | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2024-03-26 | — | — | US | disclosed |
| US-5962473-A | Methods of treating or ameliorating the symptoms of common cold or allergic rhinitis with serotonin 5-HT1F | ELI LILLY AND COMPANY (US) | 1999-10-05 | — | — | US | disclosed |
| EP-0832650-A2 | Use of serotonin 5-HT1F agonists for the prevention of migraine | ELI LILLY AND COMPANY (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1998011895-A1 | A METHOD FOR THE PREVENTION OF MIGRAINE | ELI LILLY AND COMPANY (US) | 1998-03-26 | — | — | WO | disclosed |
| EP-0824917-A2 | Use of a serotonin 5-HTlf agonist in the manufacture of a medicament for treating or ameliorating the symptoms of common cold or allergic rhinitis | ELI LILLY AND COMPANY (US) | 1998-02-25 | — | — | EP | disclosed |
| WO-1998006402-A1 | TREATMENT OF THE COMMON COLD OR ALLERGIC RHINITIS | ELI LILLY AND COMPANY (US) | 1998-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11939301-B2 | 5HT1F receptor agonists and mitochondrial biogenesis | HTR1F, HTR1A, TFAM | HTR1D 5/4885HTR1B 9/4885HTR1A 2/4885 |
| US-20260125645-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | HTR1F, HTR1A, HTR1D | HTR1D 3/4885HTR1B 4/4885HTR1A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.